Mhamed Harif

Mhamed Harif

Auto-generated profile, based on publicly available information

Mhamed Harif

Centre Hospitalier Universitaire Mohammed VI, 6 Rue Ibn Sina, Amarchich, Marrakech, Maroc

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2008 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
MHMhamed Harif
Mhamed Harif
SBSihem Barsaoui
Sihem Barsaoui
SBSaid Benchekroun
Said Benchekroun
RBRachid Bouhas
Rachid Bouhas
PDPierre Doumbé
Pierre Doumbé
JLJean Lemerle
Jean Lemerle

24 October 2011 in Arab Journal of Nephrology and Transplantation
Verified
Journal Article
Closed access
PDF file
ITIllias Tazi
Illias Tazi
HNH Nafil
H Nafil
JEJ Elhoudzi
J Elhoudzi
LML Mahmal
L Mahmal
MHM Harif
M Harif
Introduction: Tumor lysis syndrome (TLS) is a serious complication of malignancies and can result in renal failure or death. Review: In tumors with a high proliferative rate with a relatively large mass and a high sensitivity to cytotoxic agents, the initiation of therapy often results in the rapid release of intracellular anions, cations and the metabolic products of proteins and nucleic acids into the bloodstream. The increased concentrations of uric acid, phosphates, potassium and urea can overwhelm the body’s homeostatic mechanisms to process and excrete these materials and result in the clinical spectrum associated with TLS. Typical clinical sequelae include gastrointestinal disturbances, neuromuscular effects, cardiovascular complications, acute renal failure and death. Tumor lysis syndrome can also compromise the efficacy or administration of curative therapies. Available evidence suggests that the incidence of clinical TLS is approximately 3–7% for acute leukemias and 4–11% for lymphomas. Pediatric cancers are the leading cause of death by disease in children. The most common pediatric cancers include the leukemias, lymphomas, central nervous system tumors and neuroblastoma. Thus, TLS is a major concern to practitioners caring for pediatric oncology patients. Given the complexity of TLS prevention and treatment, a multidisciplinary approach involving the collaboration of medical oncologists/ hematologists and nephrologists has the greatest potential of ensuring optimal patient outcomes. Rehydration is fundamental in the management of TLS in addition to the current standard therapy for hyperuricemia which include rasburicase and allopurinol. Conclusion: The early recognition and treatment of metabolic abnormalities often prevents the severe and life-threatening complications associated with tumor lysis syndrome. Keyswords: Acute Renal Failure; Burkitt’s Lymphoma; Hematologic Malignancies; Hydration; Tumor Lysis Syndrome

1 October 2007
Verified
Journal Article
Closed access
JLJ Lemerle
J Lemerle
SBS Barsaoui
S Barsaoui
MHM Harif
M Harif
KHK Hireche
K Hireche
YLY Ladjadj
Y Ladjadj
FAF Msefer Alaoui
F Msefer Alaoui

30 June 2009 in Archives de Pédiatrie
Verified
Journal Article
Closed access
MHM. Harif
M. Harif
AMA. Madani
A. Madani
LHL. Hessissen
L. Hessissen
SZS. Zafad
S. Zafad
MKM. Khattab
M. Khattab
SBS. Benchekroun
S. Benchekroun


1 November 1996
Verified
Journal Article
Closed access
OEO Essadki
O Essadki
NWN El Wady
N El Wady
ASA El Abassi Skalli
A El Abassi Skalli
MHM Harif
M Harif
SBS Benchekroun
S Benchekroun
RKR Kadiri
R Kadiri